title: Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
abstract: BACKGROUND
  Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option.
  
  
  METHODS
  Clinical trials for biliary and hepatic carcinoma have been reviewed.
  
  
  RESULTS
  We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m(2) d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).
authors.affiliation: O.U.C. Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto, IOV - IRCCS, Padua, Italy. dpastorelli@ulss16.padova.it
authors.forename: D
authors.initials: D
authors.lastname: Pastorelli
authors.forename: G
authors.initials: G
authors.lastname: Cartei
authors.forename: F
authors.initials: F
authors.lastname: Zustovich
authors.forename: F
authors.initials: F
authors.lastname: Marchese
authors.forename: G
authors.initials: G
authors.lastname: Artioli
authors.forename: S
authors.initials: S
authors.lastname: Zovato
authors.forename: S
authors.initials: S
authors.lastname: Binato
authors.forename: R
authors.initials: R
authors.lastname: Ceravolo
authors.forename: S
authors.initials: S
authors.lastname: Cingarlini
authors.forename: F
authors.initials: F
authors.lastname: Salmaso
authors.forename: M
authors.initials: M
authors.lastname: Mattiazzi
authors.forename: C
authors.initials: C
authors.lastname: Sanavio
authors.forename: F
authors.initials: F
authors.lastname: Farinati
authors.forename: G
authors.initials: G
authors.lastname: Zanus
authors.forename: U
authors.initials: U
authors.lastname: Cillo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D004317:Doxorubicin; D000093542:Gemcitabine